ArticleThe Annals of thoracic surgery2026
Transcatheter vs Surgical Tricuspid Valve Repair: An Analysis of Medicare Beneficiaries.
Article in The Annals of thoracic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundIn patients with tricuspid regurgitation, surgical and transcatheter interventions aim to impact outcomes and symptomatic quality of life. We compared tricuspid transcatheter edge-to-edge repair (T-TEER) to isolated surgical tricuspid valve repair (TVr).
methodsAssessing US Medicare data (2018-2022), excluding endocarditis and rheumatic disease, we evaluated all patients undergoing isolated T-TEER (n = 1540) or isolated TVr (n = 1221). International Classification of Diseases 10th revision codes were used to define comorbidities and frailty using validated metrics. Doubly robust risk adjustment was performed with inverse probability weighting, multilevel regression, and competing-risk time-to-event analyses. Outcomes of interest include procedural mortality, pacemaker, and kidney injury as well as 3-year freedom from death, valve reintervention, and heart failure readmission.
resultsSurgical TVr was associated with higher unadjusted hospital mortality (8.8% vs 2.1%, P < .001), but lower 3-year mortality (20.8% vs 26.2%, P = .025) and valve reintervention (0.9% vs 2.1%, P = .015). After risk adjustment, surgical TVr was associated with higher hospital mortality (odds ratio, 2.83, P < .001) but improved longitudinal survival compared with T-TEER (hazard ratio [HR], 0.76; P = .012). Surgical TVr was associated with lower rates of overall readmission (HR, 0.87; P = .040), heart failure-related readmission (HR, 0.79; P = .001), and valve reintervention (HR, 0.83; P = .003) at 3 years compared with T-TEER.
conclusionsAmong Medicare patients with symptomatic tricuspid regurgitation, surgical TVr was associated with higher perioperative risk, but improved risk-adjusted 3-year survival, heart failure readmission, and valve reintervention compared with T-TEER. These contemporary data may inform future trial designs and heart team decision-making for patients with severe symptomatic tricuspid regurgitation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.